Eton Pharmaceuticals (ETON) Total Non-Current Liabilities (2017 - 2026)
Eton Pharmaceuticals (ETON) posted Total Non-Current Liabilities of $60.7 million for Q4 2025, down 21.59% sequentially from $77.4 million in Q3 2025, and up 21.77% YoY from $49.9 million in Q4 2024.
Eton Pharmaceuticals (ETON) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends
Eton Pharmaceuticals has reported Total Non-Current Liabilities for 5 years, with the latest figure at $60.7 million in Q4 2025.
- Quarterly Total Non-Current Liabilities rose 21.77% year-over-year to $60.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $60.7 million (up 21.77% YoY) and the FY2025 annual result came in at $60.7 million, up 21.77% from the prior year.
- Total Non-Current Liabilities eased to $60.7 million in Q4 2025 per ETON's latest filing, from $77.4 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $77.4 million in Q3 2025 and troughed at $16.3 million in Q4 2023.
- A 3-year average of $55.5 million and a median of $58.1 million in 2025 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities jumped 206.62% in 2024, then increased 21.77% in 2025.
- Over 3 years, Total Non-Current Liabilities stood at $16.3 million in 2023, then surged by 206.62% to $49.9 million in 2024, then grew by 21.77% to $60.7 million in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $60.7 million, $77.4 million, and $73.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 334.00 Mn |
| 10 | Eton Pharmaceuticals | 1.67 Bn | 1.64 Bn | 25.41 Mn | 65.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65.29 Mn |
| Dec 31, 2025 | 60.72 Mn |
| Sep 30, 2025 | 77.44 Mn |
| Jun 30, 2025 | 73.45 Mn |
| Mar 31, 2025 | 55.43 Mn |
| Dec 31, 2024 | 49.87 Mn |
| Dec 31, 2023 | 16.26 Mn |
| Sep 30, 2018 | 1.20 Mn |
| Dec 31, 2017 | 793,000.00 |